All Comments by Boris Schmidt

  1. Dyeing Worms for an Extra-Long, Healthy Lifespan?
  2. Resveratrol selectively remodels soluble oligomers and fibrils of amyloid Abeta into off-pathway conformers.
  3. Nonspecificity of binding of gamma-secretase modulators to the amyloid precursor protein.
  4. Modulation of gamma-secretase specificity using small molecule allosteric inhibitors.
  5. Selective modulation of amyloid-beta peptide degradation by flurbiprofen, fenofibrate, and related compounds regulates Abeta levels.
  6. Design, synthesis and structure-activity relationships of 1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3beta.
  7. Chicago: Out of the Blue—A Tau-based Treatment for AD?
  8. Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade.
  9. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers.
  10. Platinum-based inhibitors of amyloid-beta as therapeutic agents for Alzheimer's disease.
  11. Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease.
  12. Expression profiling in APP23 mouse brain: inhibition of Abeta amyloidosis and inflammation in response to LXR agonist treatment.
  13. Presenilin Loss of Function—Plan B for AD?
  14. Intra- or intercomplex binding to the gamma-secretase enzyme. A model to differentiate inhibitor classes.
  15. Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139.